^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | THAL-SNS-032 (CDK9 degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
Published date:
05/13/2022
Excerpt:
The novel CDK9 PROTAC, THAL-SNS-032, displayed a profound inhibitory activity in MCF7, T47D, and BT474 cells, with less effect in SKBR3, HCC1569, HCC1954, MDA-MB-231, HS578T, and BT549 cells. The three cell lines with HER2 overexpression and no presence of ER, SKBR3, HCC1569, and HCC1954 displayed an EC50 three times higher compared to ER-positive and dual ER/HER2-positive cell lines.
DOI:
10.3390/ijms23105476